According to our (Global Info Research) latest study, the global Neonatal Genetic Disease Diagnosis market size was valued at US$ 2017 million in 2025 and is forecast to a readjusted size of US$ 3844 million by 2032 with a CAGR of 9.6% during review period.
In 2025, global Neonatal Genetic Disease Diagnosis production reached approximately 10.59 million tests, with an average global market price of around USD 185 per test.
The gross profit margin of major companies in the industry is between 32.45%–55.36%.
In 2025, the global production capacity of Neonatal Genetic Disease Diagnosis was approximately 13.94 million tests.
Neonatal Genetic Disease Diagnosis refers to genetic testing and related diagnostic services used to identify inherited or congenital diseases in newborns. It may involve targeted panels, sequencing, copy number analysis, biochemical confirmation and clinical interpretation based on blood spots, blood samples or other neonatal specimens. The product scope covers diagnostic test kits, laboratory-developed testing services, sequencing-based screening and confirmatory genetic diagnosis for newborn diseases. It excludes prenatal testing, adult genetic testing, routine biochemical newborn screening without genetic analysis and general pediatric diagnostics unrelated to inherited disease.
The industry chain includes sample collection materials, nucleic acid extraction reagents, sequencing reagents, assay kits, bioinformatics tools, laboratory instruments, databases and quality control materials. Midstream activities include sample processing, genetic testing, data analysis, variant interpretation, report generation and clinical consultation. Downstream users include hospitals, newborn screening centers, clinical laboratories, pediatric departments, public health programs and families. Demand is driven by early disease detection, declining sequencing costs, expanded screening panels, rare disease awareness and healthcare policies supporting early intervention.
Improved national prenatal and newborn healthcare system plus birth defect prevention policies expand neonatal genetic disease diagnosis market. Early screening achieves timely intervention to reduce congenital disease incidence. High-throughput testing technology continuously improves detection coverage and accuracy.
This report is a detailed and comprehensive analysis for global Neonatal Genetic Disease Diagnosis market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neonatal Genetic Disease Diagnosis market size and forecasts, in consumption value ($ Million), 2021-2032
Global Neonatal Genetic Disease Diagnosis market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Neonatal Genetic Disease Diagnosis market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Neonatal Genetic Disease Diagnosis market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neonatal Genetic Disease Diagnosis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neonatal Genetic Disease Diagnosis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GeneDx, Revvity, Labcorp, Quest Diagnostics, Centogene, Baylor Genetics, Fulgent Genetics, ARUP Laboratories, BGI Genomics, Berry Genomics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Neonatal Genetic Disease Diagnosis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Targeted Gene Panel Testing
Whole Exome Sequencing
Whole Genome Sequencing
Market segment by Disease Coverage
Inherited Metabolic Disease Diagnosis
Primary Immunodeficiency Diagnosis
Neuromuscular and Developmental Disorder Diagnosis
Market segment by Turnaround Time
Rapid Diagnosis(≤7 days)
Standard Diagnosis(8–21 days)
Extended Diagnosis(>21 days)
Market segment by Application
Hospitals
Third-Party Clinical Laboratories
Public Health Screening Centers
Other
Market segment by players, this report covers
GeneDx
Revvity
Labcorp
Quest Diagnostics
Centogene
Baylor Genetics
Fulgent Genetics
ARUP Laboratories
BGI Genomics
Berry Genomics
Annoroad Gene Technology
CapitalBio Technology
KingMed Diagnostics
Novogene
Da An Gene
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neonatal Genetic Disease Diagnosis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neonatal Genetic Disease Diagnosis, with revenue, gross margin, and global market share of Neonatal Genetic Disease Diagnosis from 2021 to 2026.
Chapter 3, the Neonatal Genetic Disease Diagnosis competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neonatal Genetic Disease Diagnosis market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neonatal Genetic Disease Diagnosis.
Chapter 13, to describe Neonatal Genetic Disease Diagnosis research findings and conclusion.
Summary:
Get latest Market Research Reports on Neonatal Genetic Disease Diagnosis. Industry analysis & Market Report on Neonatal Genetic Disease Diagnosis is a syndicated market report, published as Global Neonatal Genetic Disease Diagnosis Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Neonatal Genetic Disease Diagnosis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.